Intec Pharma’s clinical programmes to validate the utility of its unique drug delivery platform, the accordion pill (AP), are ongoing. The company announced with its Q317 report that patient enrolment for the Phase III AP-CDLD (carbidopa and levodopa) in Parkinson’s has been increased to 420 patients (from 328). We now expect full enrolment in Q318. Additionally, Intec is redesigning AP-CBD/THC (cannabidiol and tetrahydrocannabinol) for a second Phase I trial and the indication is not yet specified.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs